HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma.

AUTOR(ES)

Miller, T P

RESUMO

The clinical utility for establishing the immune phenotype in patients with non-Hodgkin's lymphoma is controversial. To help resolve this dilemma, we studied 104 consecutive patients with diffuse large cell lymphoma, the most common subtype of potentially curable non-Hodgkin's lymphomas. The presence or absence of the human class II histocompatibility antigen was determined using the monoclonal antibody anti-HLA-DR (Ia), and the results correlated with pretreatment clinical features and survival. We found that eight HLA-DR negative patients had similar pretreatment clinical characteristics compared with 96 HLA-DR positive patients, but HLA-DR negative patients had a significantly shorter survival duration compared with HLA-DR positive patients (P = 0.003 log-rank). The median survival of the HLA-DR negative patients was 0.5 years compared to 2.8 yr for the HLA-DR positive patients. No HLA-DR negative patient survived beyond 1.5 yr. A multi-variate analysis, adjusting for prognostic factors of known clinical significance, confirmed the importance of HLA-DR as a prognostic factor (P = 0.016). We conclude that determining the presence of HLA-DR is a relatively simple pretreatment study that identifies a small but important group of patients who are not curable using currently available combination chemotherapy.

Documentos Relacionados

• HLA-DR expression and soluble HLA-DR levels in septic patients after trauma.
• Cytokine Production and Monocyte HLA-DR Expression as Predictors of Outcome for Patients with Community-Acquired Severe Infections
• Alleles HLA-DR in patients with polyarteritis nodosa and microscopic polyangiitis
• Analysis of restriction fragment length polymorphism for the HLA-DR gene in Japanese patients with sarcoidosis.
• Aberrant expression of HLA-DR antigen in diffuse sclerosing variant of papillary carcinoma of thyroid.